- Home
- ERNA
as 06-02-2025 4:00pm EST
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 14.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 306.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.15 - $2.63 | Next Earning Date: | 06-13-2025 |
| Revenue: | $535,000 | Revenue Growth: | 365.22% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Eterna Therapeutics Inc. (ERNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cherington Charles | ERNA | 10% Owner | Apr 2 '25 | Buy | $0.10 | 3,768,397 | $394,174.33 | 20,401,602 |
Latest Eterna Therapeutics Inc. News
ERNA Breaking Stock News: Dive into ERNA Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
GlobeNewswire
20 days ago
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
Newsfile
a month ago
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference
GlobeNewswire
a month ago
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
GlobeNewswire
a month ago
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
MT Newswires
2 months ago
Eterna Therapeutics Insider Bought Shares Worth $394,174, According to a Recent SEC Filing
GlobeNewswire
2 months ago
Ernexa Therapeutics Closes New Funding Round
GlobeNewswire
2 months ago
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
Compare ERNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ERNA Eterna Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.